Figure 2
CD8+ T-cell subset composition of CD19-CAR–modified standard and TSCM-enriched products. (A) Flow cytometry analyses of cells from a representative healthy donor (HD) at different steps of the 9-day manufacturing processes for the generation of CD19-CAR–modified standard and TSCM-enriched products. Data are shown after gating on live cells (left panels) or live CD3+ T cells (right panels). Numbers indicate the percentage of cells in each gate. (B) Fold expansion of CD19-CAR–modified T cells generated under standard and TSCM-enriched culture conditions. Data represent results from 6 HD; mean value ± SEM is indicated (*P < .05; Wilcoxon matched-pairs signed rank test). (C) Percentage of CD19-CAR–transduced T cells in standard and TSCM-enriched products. Data represent results from 6 HDs; mean value ± SEM is indicated. (D) Percentage of CD8+ T-cell subsets in the CD19-CAR–modified standard and TSCM-enriched products. TSCM were defined as CD3+CD8+CD45RO−CCR7+CD45RA+CD62L+CD27+CD95+ cells; TCM as CD3+CD8+CCR7+CD45RO+; TEM as CD3+CD8+CCR7−CD45RO+; TTE as CD3+CD8+CCR7−CD45RO−; other cells as CD3+CD8+CCR7+CD45RO− not displaying the full TSCM phenotype. Data representing results from 6 HDs are shown as box-and-whisker plots extending to minimum and maximum values. Bands inside the box represent median values. (E) Theoretical number of CD19-CAR+CD8+ TSCM obtainable from stimulation of 1 × 108 PBMCs (standard products) or Fab-streptamer–enriched CD8+ TN (TSCM-enriched products). Data represent results from 6 HDs (*P < .05; Wilcoxon matched-pairs signed rank test).

CD8+ T-cell subset composition of CD19-CAR–modified standard and TSCM-enriched products. (A) Flow cytometry analyses of cells from a representative healthy donor (HD) at different steps of the 9-day manufacturing processes for the generation of CD19-CAR–modified standard and TSCM-enriched products. Data are shown after gating on live cells (left panels) or live CD3+ T cells (right panels). Numbers indicate the percentage of cells in each gate. (B) Fold expansion of CD19-CAR–modified T cells generated under standard and TSCM-enriched culture conditions. Data represent results from 6 HD; mean value ± SEM is indicated (*P < .05; Wilcoxon matched-pairs signed rank test). (C) Percentage of CD19-CAR–transduced T cells in standard and TSCM-enriched products. Data represent results from 6 HDs; mean value ± SEM is indicated. (D) Percentage of CD8+ T-cell subsets in the CD19-CAR–modified standard and TSCM-enriched products. TSCM were defined as CD3+CD8+CD45ROCCR7+CD45RA+CD62L+CD27+CD95+ cells; TCM as CD3+CD8+CCR7+CD45RO+; TEM as CD3+CD8+CCR7CD45RO+; TTE as CD3+CD8+CCR7CD45RO; other cells as CD3+CD8+CCR7+CD45RO not displaying the full TSCM phenotype. Data representing results from 6 HDs are shown as box-and-whisker plots extending to minimum and maximum values. Bands inside the box represent median values. (E) Theoretical number of CD19-CAR+CD8+ TSCM obtainable from stimulation of 1 × 108 PBMCs (standard products) or Fab-streptamer–enriched CD8+ TN (TSCM-enriched products). Data represent results from 6 HDs (*P < .05; Wilcoxon matched-pairs signed rank test).

Close Modal

or Create an Account

Close Modal
Close Modal